Abstract
Osteoarthritis (OA) is a progressive disorder characterized by destruction of articular cartilage and subchondral bone, and by synovial changes. The diagnosis of OA is generally based on clinical and radiographic changes, which occur fairly late during disease progression and have poor sensitivity for monitoring disease progression. Progression of joint damage is likely to result primarily from an imbalance between cartilage degradation and repair, so measuring markers of these processes would seem a promising approach to improve the prediction of disease progression at the individual level. Moreover, genetic markers might be useful predictors of prognosis. The lack of fully effective, chondroprotective medications has limited the use of such potential markers to monitor the effect of treatment for OA. Nevertheless, owing to their dynamic changes in response to treatment, biological markers might provide relevant information more rapidly than imaging techniques (such as radiography and MRI) can, and should contribute to our understanding of mechanisms that underlie the clinical efficacy of OA treatments. Most of the identified genes involved in OA encode signal-transduction proteins, which provide the potential for novel therapeutic approaches. In this Review, we will use the recently proposed BIPED (i.e. burden of disease, investigative, prognostic, efficacy of intervention and diagnostic) classification of OA markers to describe the potential usage of a given marker.
Key Points
-
Although levels of some biomarkers of joint metabolism might be significantly increased in groups of patients with early stages of osteoarthritis (OA), these markers cannot be used as diagnostic tests for OA in individual patients
-
'Burden of disease' markers can only be used for clinical studies, because the individual values obtained in groups of patients with different degrees of OA burden overlap
-
The combined use of several markers seems to be necessary to improve the prediction of disease progression at the individual level; genetic markers might contribute to the prognostic assessment of patients with OA
-
Owing to their rapid changes in response to therapy, biological markers might provide relevant information more rapidly than imaging techniques (radiography and MRI) can, and should contribute to our understanding of mechanisms underlying the clinical efficacy of treatments for OA
-
Validation of genetic approaches is awaited, but in the meantime they provide new information on the pathogenesis of OA and might lead to the identification of new markers with potential clinical utility
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Blackburn WD Jr et al. (1996) Cartilage imaging in osteoarthritis. Semin Arthritis Rheum 25: 273–281
Fex E et al. (1996) Development of radiographic damage during the first 5–6 yr of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort. Br J Rheumatol 35: 1106–1115
Garnero P et al. (2000) Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum 43: 953–968
Melkko J et al. (1994) Clearance of NH2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 179: 405–412
Bauer DC et al. (2006) Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 14: 723–727
Stewart A et al. (1999) Bone density and bone turnover in patients with osteoarthritis and osteoporosis. J Rheumatol 26: 622–626
Bettica P et al. (2002) Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 46: 3178–3184
Sowers M et al. (1999) The associations of bone mineral density and bone turnover markers with osteoarthritis of the hand and knee in pre- and perimenopausal women. Arthritis Rheum 42: 483–489
Hunter DJ et al. (2003) The role of bone metabolism in osteoarthritis. Curr Rheumatol Rep 5: 15–19
Elsaid KA and Chichester CO (2006) Review: collagen markers in early arthritic diseases. Clin Chim Acta 365: 68–77
Shinmei M et al. (1993) Joint fluid carboxy-terminal type II procollagen peptide as a marker of cartilage collagen biosynthesis. Osteoarthritis Cartilage 1: 121–128
Nelson F et al. (1998) Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 102: 2115–2125
Rousseau JC et al. (2004) Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 12: 440–447
Olsen A et al. (2007) Anabolic and catabolic function of chondrocytes ex vivo is reflected by the metabolic processing of type II collagen. Osteoarthritis Cartilage 15: 335–342
Deberg M et al. (2005) New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 13: 258–265
Charni N et al. (2005) Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 52: 1081–1090
Christgau S et al. (2001) Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 29: 209–215
Rizkalla G et al. (1992) Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest 90: 2268–2277
Vilim V et al. (2001) Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage 9: 612–618
Verzijl N et al. (2003) AGEing and osteoarthritis: a different perspective. Curr Opin Rheumatol 15: 616–622
Lohmander LS et al. (2005) Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis. Arthritis Rheum 52: 3160–3167
Dean DD et al. (1989) Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 84: 678–685
Garnero P et al. (2001) Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 60: 619–626
Elliott AL et al. (2005) Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis Rheum 52: 105–111
Johansen JS et al. (1996) Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 35: 553–559
Dragomir AD et al. (2002) Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology. Osteoarthritis Cartilage 10: 687–691
Bleasel JF et al. (1999) Changes in serum cartilage marker levels indicate altered cartilage metabolism in families with the osteoarthritis-related type II collagen gene COL2A1 mutation. Arthritis Rheum 42: 39–45
Kelman A et al. (2006) Association of higher levels of serum cartilage oligomeric matrix protein and N-telopeptide crosslinks with the development of radiographic hip osteoarthritis in elderly women. Arthritis Rheum 54: 236–243
Sowers M et al. (2002) C-reactive protein as a biomarker of emergent osteoarthritis. Osteoarthritis Cartilage 10: 595–601
Lohmander LS et al. (1996) Procollagen II C-propeptide in joint fluid: changes in concentration with age, time after knee injury, and osteoarthritis. J Rheumatol 23: 1765–1769
Chevalier X et al. (2005) Biological markers for osteoarthritis: an update. Joint Bone Spine 72: 106–109
Takahashi M et al. (2004) Relationship between radiographic grading of osteoarthritis and the biochemical markers for arthritis in knee osteoarthritis. Arthritis Res Ther 6: R208–R212
Clark AG et al. (1999) Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 42: 2356–2364
Garnero P et al. (2004) Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study. Arthritis Rheum 50: 3137–3144
Bruyere O et al. (2003) Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis. J Rheumatol 30: 1043–1050
Sugiyama S et al. (2003) Procollagen II C propeptide level in the synovial fluid as a predictor of radiographic progression in early knee osteoarthritis. Ann Rheum Dis 62: 27–32
Reijman M et al. (2004) A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 50: 2471–2478
Mazieres B et al. (2006) Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort. Ann Rheum Dis 65: 354–359
Bruyere O et al. (2006) Osteoarthritis, magnetic resonance imaging and biochemical markers: a one year prospective study. Ann Rheum Dis 65: 1050–1054
Mazzuca SA et al. (2006) Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis. J Rheumatol 33: 1147–1151
Deberg MA et al. (2005) One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cartilage 13: 1059–1065
Chevalier X et al. (2001) Tissue inhibitor of metalloprotease-1 (TIMP-1) serum level may predict progression of hip osteoarthritis. Osteoarthritis Cartilage 9: 300–307
Pavelka K et al. (2004) Hyaluronic acid levels may have predictive value for the progression of knee osteoarthritis. Osteoarthritis Cartilage 12: 277–283
Sharif M et al. (2004) Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. Arthritis Rheum 50: 2479–2488
Garnero P et al. (2002) Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46: 2613–2624
Sharif M et al. (2007) A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis—association with disease progression. Rheumatology (Oxf) [doi 10.1093/rheumatology/kel409]
Garnero P et al. (2006) Increased urinary type II collagen helical and C-telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis. Ann Rheum Dis 65: 1639–1644
Sharma L et al. (2004) The ratio of collagen breakdown to collagen synthesis and its relationship with the progression of knee osteoarthritis. Presented at the 68th Annual Scientific Meeting of the American College of Rheumatology: 2004 October 17–21 San Antonio, TX, USA: S642
Lehmann HJ et al. (2002) Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 61: 530–533
Spector TD et al. (2005) Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 7: R625–R633
Gineyts E et al. (2004) Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann Rheum Dis 63: 857–861
Gineyts E et al. (2004) Effects of rofecoxib on urinary excretion of type II collagen C-telopeptide (CTX II) and glucosyl–galactosyl–pyridinoline (GLC GAL PYD) levels, markers of cartilage and synovium degradation respectively in patients with osteoarthritis (OA) of the knee. Presented at the 68th Annual Scientific Meeting of the American College of Rheumatology: 2004 October 17–21 San Antonio, TX, USA: S344
Bruyere O et al. (2004) Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause 11: 138–143
Christgau S et al. (2004) Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clin Exp Rheumatol 22: 36–42
Cibere J et al. (2005) Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers. J Rheumatol 32: 896–902
Leff RL et al. (2003) Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor. J Rheumatol 30: 544–549
Christgau S et al. (2004) Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 11: 508–518
Arjmandi BH et al. (2003) Soy protein has a greater effect on bone in postmenopausal women not on hormone replacement therapy, as evidenced by reducing bone resorption and urinary calcium excretion. J Clin Endocrinol Metab 88: 1048–1054
Manicourt DH et al. (2006) Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 54: 3205–3211
Lamers RJ et al. (2005) Identification of an urinary metabolite profile associated with osteoarthritis. Osteoarthritis Cartilage 13: 762–768
Peach CA et al. (2005) Recent advances in the genetic investigation of osteoarthritis. Trends Mol Med 11: 186–191
Kamarainen OP et al. (2006) Aggrecan core protein of a certain length is protective against hand osteoarthritis. Osteoarthritis Cartilage 14: 1075–1080
Pratta MA et al. (2006) Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments. Osteoarthritis Cartilage 14: 702–713
Acknowledgements
Désirée Lie, University of California, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the Medscape-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Rousseau, JC., Delmas, P. Biological markers in osteoarthritis. Nat Rev Rheumatol 3, 346–356 (2007). https://doi.org/10.1038/ncprheum0508
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0508
This article is cited by
-
Past, present, and future of cartilage restoration: from localized defect to arthritis
Knee Surgery & Related Research (2022)
-
Genetic markers of osteoarthritis: early diagnosis in susceptible Pakistani population
Journal of Orthopaedic Surgery and Research (2021)
-
MMP-13 enzyme and pH responsive theranostic nanoplatform for osteoarthritis
Journal of Nanobiotechnology (2020)
-
Association between changes in molecular biomarkers of cartilage matrix turnover and changes in knee articular cartilage: a longitudinal pilot study
Journal of Experimental Orthopaedics (2019)
-
Intra-articular treatment options for knee osteoarthritis
Nature Reviews Rheumatology (2019)